| Literature DB >> 32536642 |
Nobuo Sasaki1, Hideya Yamamoto2, Ryoji Ozono3, Ryo Maeda1, Yasuki Kihara4.
Abstract
Objective It is well known that poor sleep increases the risk of heart failure (HF). However, the underlying mechanisms remain unclear. In this study, we investigated the association of poor sleep with hemodynamic stress on the left ventricle, which was a key factor for the development of HF in elderly individuals. Methods A total of 2,301 participants (≥65 years old) without cardiac disease were enrolled in this cross-sectional analysis. We evaluated the subjective sleep quality, sleeping difficulty, subjective sleep duration, use of sleeping pills, and daytime dysfunction using the Pittsburgh Sleep Quality Index, a 19-item self-reported questionnaire. We assessed serum N-terminal pro-brain natriuretic peptide (NT-proBNP) as a marker of hemodynamic stress on the left ventricle, and we defined high NT-proBNP as a serum NT-proBNP level ≥ 125 pg/mL. Results Sleeping difficulty was significantly associated with high NT-proBNP levels [odds ratio (OR), 1.46; 95% confidence interval (CI), 1.16-1.85; p<0.005]. A subjective short sleep duration was also significantly associated with high NT-proBNP levels (OR, 1.69; 95% CI, 1.03-2.75; p<0.05). A subjective poor sleep quality, the use of sleeping pills, and daytime dysfunction were not associated with serum NT-proBNP levels. All data were adjusted for the age, sex, body mass index, serum hemoglobin concentration, serum creatinine level, systolic blood pressure, diastolic blood pressure, and use of antihypertensive medications. Conclusion Poor sleep was associated with high hemodynamic stress to the left ventricle in elderly population.Entities:
Keywords: brain; elderly; heart failure; natriuretic peptide; sleep
Year: 2020 PMID: 32536642 PMCID: PMC7578600 DOI: 10.2169/internalmedicine.4470-20
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.Flowchart for the selection of participants. HIRSH study, Hiroshima Sleep and Healthcare study; NT-proBNP: N-terminal pro-brain natriuretic peptide
Characteristics and Results of Pittsburgh Sleep Quality Index in Participants.
| N | 2,301 | |
| Mean age | (years) | 75.7±5.3 |
| Female | [n (%)] | 1,250 (54) |
| BMI | (kg/m2) | 22.9±3.1 |
| Hemoglobin | (g/dL) | 13.3±1.4 |
| Creatinine | (mg/dL) | 0.79±0.21 |
| SBP | (mmHg) | 133±17 |
| DBP | (mmHg) | 74±11 |
| Current smoker | [n (%)] | 178 (8) |
| Habitual drinker | [n (%)] | 689 (30) |
| Antihypertensive medications | [n (%)] | 958 (42) |
| Diabetes | [n (%)] | 298 (13) |
| Dyslipidaemia | [n (%)] | 583 (25) |
| History of stroke | [n (%)] | 130 (6) |
| NT-proBNP† | (pg/mL) | 78 (46–136) |
| High NT-proBNP | [n (%)] | 664 (29) |
| Global PSQI score | 5.1±3.2 | |
| C1 score | 1.0±0.6 | |
| C2 score | 0.9±0.9 | |
| C3 score | 1.1±0.9 | |
| C4 score | 0.6±0.9 | |
| C5 score | 0.7±0.5 | |
| C6 score | 0.5±1.1 | |
| C7 score | 0.2±0.5 | |
| Subjective poor sleep quality | [n (%)] | 442 (19) |
| Sleeping difficulty | [n (%)] | 495 (22) |
| Short sleep duration | [n (%)] | 86 (4) |
| Use of sleeping pills | [n (%)] | 483 (21) |
| Daytime dysfunction | [n (%)] | 495 (22) |
Hypertension was defined as taking anti-hypertensive medications and/or having systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Subjective poor sleep quality, sleep difficulty, short sleep duration, use of sleeping pills, and daytime dysfunction were defined as C1 score ≥ 2, the sum of C2, C4 and C5 scores ≥ 4, C3 score ≥ 3, C6 score ≥ 1, and C7 score ≥ 1, respectively. The scores from C1 to C7 were components of PSQI. High NT-proBNP was defined as serum NT-proBNP level ≥ 125 pg/mL. †Data are given as median (interquartile range, 25–75%). BMI: body mass index, DBP: diastolic blood pressure, NT-proBNP: N-terminal pro-brain natriuretic peptide, PSQI: Pittsburgh Sleep Quality Index, SBP: systolic blood pressure
Figure 2.A comparison of the proportion of participants with high NT-proBNP levels between those with and without poor sleep. A subjective poor sleep quality, sleep difficulty, short sleep duration, use of sleeping pills and daytime dysfunction were defined as C1 score ≥ 2; the sum of C2, C4, and C5 scores ≥ 4; C3 score ≥ 3; C6 score ≥ 1; and C7 score ≥ 1, respectively. The scores from C1 to C7 were components of the PSQI. High NT-proBNP was defined as a serum NT-proBNP level ≥ 125 pg/mL. NT-proBNP: N-terminal pro-brain natriuretic peptide, PSQI: Pittsburgh Sleep Quality Index
Univariate OR for High NT-proBNP (n=2,301).
| Variable | OR | 95%CI | p |
|---|---|---|---|
| Age, years | 1.14 | (1.12–1.16) | <0.001 |
| Female, yes or no | 1.24 | (1.04–1.49) | 0.019 |
| BMI, kg/m2 | 0.94 | (0.91–0.97) | <0.001 |
| Hemoglobin, g/dL | 0.63 | (0.58–0.68) | <0.001 |
| Creatinine, mg/dL | 4.57 | (2.99–7.04) | <0.001 |
| SBP, mmHg | 1.01 | (1.01–1.02) | <0.001 |
| DBP, mmHg | 0.98 | (0.97–0.99) | <0.001 |
| Current smoker, yes or no | 0.8 | (0.55–1.12) | 0.198 |
| Habitual drinker, yes or no | 0.98 | (0.81–1.19) | 0.855 |
| Antihypertensive medications, yes or no | 1.56 | (1.30–1.87) | <0.001 |
| Diabetes, yes or no | 0.98 | (0.75–1.28) | 0.892 |
| Dyslipidaemia, yes or no | 0.90 | (0.73–1.11) | 0.327 |
| History of stroke, yes or no | 1.19 | (0.81–1.73) | 0.376 |
Hypertension was defined as taking anti-hypertensive medications and/or having systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. High NT-proBNP was defined as serum NT-proBNP level ≥ 125 pg/mL. BMI: body mass index, CI: confidence interval, DBP: diastolic blood pressure, NT-proBNP: N-terminal pro-brain natriuretic peptide, OR: odds ratio, SBP: systolic blood pressure
Multivariable Adjusted OR for High NT-proBNP (n=2,301).
| Variable | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | p | OR | 95%CI | p | |
| Subjective poor sleep quality | 1.18 | (0.92–1.50) | 0.202 | |||
| Sleeping difficulty | 1.46 | (1.16–1.85) | 0.002 | 1.40 | (1.10–1.79) | 0.007 |
| Short sleep duration | 1.69 | (1.03–2.75) | 0.039 | 1.40 | (0.83–2.32) | 0.204 |
| Use of sleeping medications | 0.91 | (0.71–1.16) | 0.440 | |||
| Daytime dysfunction | 0.95 | (0.74–1.21) | 0.664 | |||
Multivariate model 1 included age, gender, body mass index, serum creatinine, hemoglobin concentration, SBP, DBP and the use of antihypertensive medications. Model 2 simultaneously included sleeping difficulty and short sleep duration.
Subjective poor sleep quality, sleep difficulty, short sleep duration, use of sleeping pills, and daytime dysfunction were defined as C1 score ≥ 2, the sum of C2, C4 and C5 scores ≥ 4, C3 score ≥ 3, C6 score ≥ 1, and C7 score ≥ 1, respectively. The scores from C1 to C7 were components of PSQI. High NT-proBNP was defined as serum NT-proBNP level ≥ 125 pg/mL. CI: confidence interval, DBP: diastolic blood pressure, NT-proBNP: N-terminal pro-brain natriuretic peptide, OR: odds ratio, PSQI: Pittsburgh Sleep Quality Index, SBP: systolic blood pressure